Kilitch Drugs (India) (BOM:524500) Cyclically Adjusted Revenue per Share: ₹44.63 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524500 Kilitch Drugs (India) Ltd BOM:524500
81 GF Score
Price ₹180.10
GF Value ₹228.28
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Cyclically Adjusted Revenue per Share?

Kilitch Drugs (India) BOM:524500 +4.98% 81 Cyclically Adjusted Revenue per Share is ₹44.63 as of Jun. 2026. GuruFocus rates BOM:524500 with a GF Score™ of 81/100 and a GF Value™ of ₹228.28 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kilitch Drugs (India)'s adjusted revenue per share for the three months ended in Jun. 2026 was ₹12.787. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹44.63 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Kilitch Drugs (India)'s average Cyclically Adjusted Revenue Growth Rate was 14.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-06), Kilitch Drugs (India)'s current stock price is ₹180.10. Kilitch Drugs (India)'s Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹44.63. Kilitch Drugs (India)'s Cyclically Adjusted PS Ratio of today is 4.04.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kilitch Drugs (India) was 5.97. The lowest was 2.99. And the median was 4.38.


Kilitch Drugs (India)  (BOM:524500) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kilitch Drugs (India)'s Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=180.10/44.63
=4.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kilitch Drugs (India) was 5.97. The lowest was 2.99. And the median was 4.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kilitch Drugs (India) Cyclically Adjusted Revenue per Share Related Terms


Kilitch Drugs (India) Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) Cyclically Adjusted Revenue per Share Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 38.02 42.93

Kilitch Drugs (India) Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.01 40.21 41.03 42.93 44.63

BOM:524500 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kilitch Drugs (India) Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kilitch Drugs (India)'s Cyclically Adjusted PS Ratio falls into.


BOM:524500
81GF Score
Kilitch Drugs (India) Ltd BOM:524500
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kilitch Drugs (India) Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kilitch Drugs (India)'s adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=12.787/167.3573*167.3573
=12.787

Current CPI (Jun. 2026) = 167.3573.

Kilitch Drugs (India) Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 1.275 83.774 2.547
201303 2.497 85.687 4.877
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 8.959 111.317 13.469
201809 9.388 115.142 13.645
201812 2.848 115.142 4.140
201903 5.750 118.202 8.141
201906 3.429 120.880 4.747
201909 4.880 123.175 6.630
201912 5.114 126.235 6.780
202003 2.336 124.705 3.135
202006 3.216 127.000 4.238
202009 5.692 130.118 7.321
202012 6.423 130.889 8.213
202103 6.213 131.771 7.891
202106 6.145 134.084 7.670
202109 7.434 135.847 9.158
202112 10.783 138.161 13.062
202203 11.118 138.822 13.403
202206 10.514 142.347 12.361
202209 9.651 144.661 11.165
202212 9.403 145.763 10.796
202303 14.032 146.865 15.990
202306 11.456 150.280 12.758
202309 12.459 151.492 13.764
202312 9.893 152.924 10.827
202403 13.416 153.035 14.672
202406 10.136 155.789 10.889
202409 14.765 157.882 15.651
202412 17.479 158.323 18.476
202503 18.628 157.552 19.787
202506 13.402 159.755 14.040
202509 14.845 162.289 15.309
202512 15.175 163.281 15.554
202603 26.167 164.272 26.658
202606 12.787 167.357 12.787

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹44.63 mean?
Kilitch Drugs (India) (BOM:524500) has a Cyclically Adjusted Revenue per Share of ₹44.63 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kilitch Drugs (India) and its competitors.
Is Kilitch Drugs (India)'s Cyclically Adjusted Revenue per Share too high?
Kilitch Drugs (India)'s current Cyclically Adjusted Revenue per Share is ₹44.63. Overall, Kilitch Drugs (India) has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Cyclically Adjusted Revenue per Share compare to ZTS?
Kilitch Drugs (India)'s Cyclically Adjusted Revenue per Share of ₹44.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kilitch Drugs (India) and its competitors. Kilitch Drugs (India)'s current Cyclically Adjusted Revenue per Share is ₹44.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (BOM:524500) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.28, compared to a current price of ₹180.10 — trading 21.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹44.63. Kilitch Drugs (India)'s overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kilitch Drugs (India) (BOM:524500), the current Cyclically Adjusted Revenue per Share is ₹44.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kilitch Drugs (India) (BOM:524500) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹180.10 is trading 21.1% below its estimated GF Value™ of ₹228.28. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for BOM:524500:

  • Cyclically Adjusted Revenue per Share: ₹44.63
  • GF Value™: ₹228.28 vs. price of ₹180.10 (21.1% below fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the BOM:524500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kilitch Drugs (India) Business Description

Other Exchanges KILITCH:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
81GF Score

Get the complete analysis for BOM:524500

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹180.10
Price
₹228.28
GF Value